Department of Obstetrics and Gynaecology, Radboud Institute for Molecular Life Sciences, Radboud university medical center, Nijmegen, The Netherlands.
Department of Obstetrics and Gynaecology, Catharina Hospital, Eindhoven, The Netherlands.
Int J Cancer. 2020 Aug 1;147(3):897-900. doi: 10.1002/ijc.32834. Epub 2019 Dec 28.
Women with cervical intraepithelial neoplasia grade 3 (CIN3) have a long-lasting increased risk for noncervical high-risk human papillomavirus (hrHPV)-related (pre)malignancies. The aim of our study was to estimate this risk in women with recurrent CIN3 compared to women without a history of CIN3 and women with a single episode of CIN3. Women with a CIN3 diagnosis between 1990 and 2010 were obtained from the Dutch Pathology Registry (PALGA) and matched with a control group of women without CIN3. Analysis has been conducted in a subset of women with recurrent CIN3, defined as reoccurrence minimally 2 years post-treatment. Cases of noncervical hrHPV-related (pre)malignancies of the anus, vulva, vagina and oropharynx were identified until 2015 and incidence rate ratios (IRRs) were estimated. Then, 1,797 women with recurrent CIN3 were included with a median age of 34 years (range 18-76) and 31,594 person-years of follow-up. Women with recurrent CIN3 had an increased risk of developing noncervical hrHPV-related (pre)malignancies compared to women without CIN3 with an IRR of 25.96 (95%CI 6.32-106.58). The IRR was 2.48 (95% CI 1.87-3.30) compared to women with a single episode of CIN3. Studies on posttreatment follow-up and prophylactic hrHPV vaccination are warranted.
患有宫颈上皮内瘤变 3 级(CIN3)的女性具有持续的、较高的非宫颈高危型人乳头瘤病毒(hrHPV)相关(前)恶性肿瘤风险。本研究旨在评估与无 CIN3 病史的女性和仅有一次 CIN3 病史的女性相比,复发 CIN3 的女性的这种风险。从荷兰病理登记处(PALGA)获取了 1990 年至 2010 年间诊断为 CIN3 的女性,并与无 CIN3 的对照组女性进行了匹配。在复发 CIN3 的女性亚组中进行了分析,定义为治疗后至少 2 年复发。直至 2015 年,确定了肛门、外阴、阴道和口咽的非宫颈 hrHPV 相关(前)恶性肿瘤的发病例数,并估计了发病率比(IRR)。然后,纳入了 1797 例复发 CIN3 的女性,中位年龄为 34 岁(范围 18-76),随访时间为 31594 人年。与无 CIN3 的女性相比,复发 CIN3 的女性发生非宫颈 hrHPV 相关(前)恶性肿瘤的风险增加,IRR 为 25.96(95%CI 6.32-106.58)。与仅有一次 CIN3 病史的女性相比,IRR 为 2.48(95%CI 1.87-3.30)。需要进行治疗后随访和预防性 hrHPV 疫苗接种的研究。